These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 9860423)

  • 1. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
    Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
    Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nephrotic syndrome after treatment with d-penicillamine in a pediatric patient with Wilson's disease].
    Farallo M; Amoruso C; Frattini C; Ardissino G; Nebbia G
    Pediatr Med Chir; 2012; 34(5):234-6. PubMed ID: 23342748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
    Hanukoglu A; Curiel B; Berkowitz D; Levine A; Sack J; Lorberboym M
    J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nephrotic syndrome after treatment with penicillamine in Wilson's disease].
    Hampel R; Meng W; Kallwellis G
    Z Gesamte Inn Med; 1976 Jul; 31(13):507-11. PubMed ID: 960872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient with late-onset Wilson's disease: deterioration with penicillamine.
    Sohtaoglu M; Ergin H; Ozekmekçi S; Gökdemir S; Sonsuz A; Arici C
    Mov Disord; 2007 Jan; 22(2):290-1. PubMed ID: 17083099
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pathogenesis and treatment of Wilson's disease].
    Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
    Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membranoproliferative glomerulonephritis in a patient with Wilson's disease.
    Ozçakar ZB; Ekim M; Ensari A; Kuloglu Z; Yüksel S; Acar B; Kirsaçlioglu C; Kansu A; Yalçinkaya F; Girgin N
    J Nephrol; 2006; 19(6):831-3. PubMed ID: 17173260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Wilson's disease with triethylene tetramine dihydrochloride. A case report.
    Haslam RH; Sass-Kortsak A; Stout W; Berg M
    Dev Pharmacol Ther; 1980; 1(5):318-24. PubMed ID: 7438976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wilson's disease and pregnancy.
    Sternlieb I
    Hepatology; 2000 Feb; 31(2):531-2. PubMed ID: 10655282
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-term D-penicillamine therapy of Wilson's disease in childhood. Changes in blood coagulation and effects on the haematopoetic system].
    Hayek HW; Schnack H; Widhalm S
    Wien Klin Wochenschr; 1973 Feb; 85(8):122-5. PubMed ID: 4632215
    [No Abstract]   [Full Text] [Related]  

  • 12. Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilson's disease.
    Berger B; Mader I; Damjanovic K; Niesen WD; Stich O
    Clin Neurol Neurosurg; 2014 Dec; 127():122-4. PubMed ID: 25459257
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of penicillamine nephropathy in Wilson's disease: a new chelating agent.
    Walshe JM
    Lancet; 1969 Dec; 2(7635):1401-2. PubMed ID: 4188283
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.
    Scheinberg IH; Jaffe ME; Sternlieb I
    N Engl J Med; 1987 Jul; 317(4):209-13. PubMed ID: 3600712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Wilson's disease: physiopathology, therapeutic approach and case report].
    Gallo V; Riva P; Sidoli L; Bisbocci D
    Minerva Gastroenterol Dietol; 1994 Dec; 40(4):197-201. PubMed ID: 7849148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of and clinical experiences with trien for the treatment of Wilson's disease in absolute intolerance of D-penicillamine.
    Harders H; Cohnen E
    Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):10-2. PubMed ID: 122652
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine).
    Dahlman T; Hartvig P; Löfholm M; Nordlinder H; Lööf L; Westermark K
    QJM; 1995 Sep; 88(9):609-16. PubMed ID: 7583074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy.
    Yalaz M; Aydogdu S; Ozgenc F; Akisu M; Kultursay N; Yagci RV
    Minerva Pediatr; 2003 Dec; 55(6):625-8. PubMed ID: 14676735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Wilson's disease.
    Brewer GJ; Yuzbasiyan-Gurkan V; Young AB
    Semin Neurol; 1987 Jun; 7(2):209-20. PubMed ID: 3332455
    [No Abstract]   [Full Text] [Related]  

  • 20. [Nephrotic syndrome secondary to d-penicillamine in a patient with Wilson's disease].
    Castellví Suaña JM; Xiol Quingles X; Castellote Alonso J; Guardiola Capón J
    Rev Clin Esp; 1993 Oct; 193(6):343-4. PubMed ID: 8259463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.